Showing 501 - 520 results of 42,130 for search '(( 5 ((we decrease) OR (nn decrease)) ) OR ( 50 ((ns decrease) OR (a decrease)) ))', query time: 0.84s Refine Results
  1. 501
  2. 502
  3. 503
  4. 504

    DataSheet2_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Among the various receptors that have been reported to interact with WNT5A, we found FZD5 abundantly expressed by eMSC when compared to unfractionated stromal cells. …”
  5. 505

    DataSheet1_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Among the various receptors that have been reported to interact with WNT5A, we found FZD5 abundantly expressed by eMSC when compared to unfractionated stromal cells. …”
  6. 506

    Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lun... by Feiyun Chang (12243382)

    Published 2022
    “…The regulation mechanism of circ_0017639 was demonstrated by a dual-luciferase reporter assay. We observed higher levels of circ_0017639 in DDP-resistant NSCLC samples and cells. …”
  7. 507
  8. 508
  9. 509
  10. 510
  11. 511

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  12. 512
  13. 513
  14. 514
  15. 515
  16. 516
  17. 517
  18. 518
  19. 519
  20. 520